New frontiers of neuropharmacologic treatment of brain injury agitation

Kathleen R. Bell, Diana C. Cardenas

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The treatment of agitation and aggression in the TBI patient continues to be a challenge in both the immediate period following injury and later, in the community setting. While there are few studies of non-traditional pharmacologic compounds in TBI subjects, studies of other patient populations with related disorders have been referenced for information on new and experimental compounds. In this article, medications such as the serotonergic system enhancers, atypical neuroleptics, central nervous system stimulants, hormonal agents, and opioid antagonists are reviewed at a basic science and clinical level. Possible directions for their use in the brain-injured patient are discussed.

Original languageEnglish
Pages (from-to)233-244
Number of pages12
JournalNeuroRehabilitation
Volume5
Issue number3
StatePublished - Jul 1 1995
Externally publishedYes

Fingerprint

Brain Injuries
Central Nervous System Stimulants
Narcotic Antagonists
Aggression
Antipsychotic Agents
Therapeutics
Wounds and Injuries
Brain
Population
Direction compound

Keywords

  • Agitation
  • Brain injury
  • Pharmacology

ASJC Scopus subject areas

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation
  • Clinical Neurology

Cite this

New frontiers of neuropharmacologic treatment of brain injury agitation. / Bell, Kathleen R.; Cardenas, Diana C.

In: NeuroRehabilitation, Vol. 5, No. 3, 01.07.1995, p. 233-244.

Research output: Contribution to journalArticle

Bell, KR & Cardenas, DC 1995, 'New frontiers of neuropharmacologic treatment of brain injury agitation', NeuroRehabilitation, vol. 5, no. 3, pp. 233-244.
Bell, Kathleen R. ; Cardenas, Diana C. / New frontiers of neuropharmacologic treatment of brain injury agitation. In: NeuroRehabilitation. 1995 ; Vol. 5, No. 3. pp. 233-244.
@article{25bc6e1069094d5db98981fe2f0ece67,
title = "New frontiers of neuropharmacologic treatment of brain injury agitation",
abstract = "The treatment of agitation and aggression in the TBI patient continues to be a challenge in both the immediate period following injury and later, in the community setting. While there are few studies of non-traditional pharmacologic compounds in TBI subjects, studies of other patient populations with related disorders have been referenced for information on new and experimental compounds. In this article, medications such as the serotonergic system enhancers, atypical neuroleptics, central nervous system stimulants, hormonal agents, and opioid antagonists are reviewed at a basic science and clinical level. Possible directions for their use in the brain-injured patient are discussed.",
keywords = "Agitation, Brain injury, Pharmacology",
author = "Bell, {Kathleen R.} and Cardenas, {Diana C.}",
year = "1995",
month = "7",
day = "1",
language = "English",
volume = "5",
pages = "233--244",
journal = "NeuroRehabilitation",
issn = "1053-8135",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - New frontiers of neuropharmacologic treatment of brain injury agitation

AU - Bell, Kathleen R.

AU - Cardenas, Diana C.

PY - 1995/7/1

Y1 - 1995/7/1

N2 - The treatment of agitation and aggression in the TBI patient continues to be a challenge in both the immediate period following injury and later, in the community setting. While there are few studies of non-traditional pharmacologic compounds in TBI subjects, studies of other patient populations with related disorders have been referenced for information on new and experimental compounds. In this article, medications such as the serotonergic system enhancers, atypical neuroleptics, central nervous system stimulants, hormonal agents, and opioid antagonists are reviewed at a basic science and clinical level. Possible directions for their use in the brain-injured patient are discussed.

AB - The treatment of agitation and aggression in the TBI patient continues to be a challenge in both the immediate period following injury and later, in the community setting. While there are few studies of non-traditional pharmacologic compounds in TBI subjects, studies of other patient populations with related disorders have been referenced for information on new and experimental compounds. In this article, medications such as the serotonergic system enhancers, atypical neuroleptics, central nervous system stimulants, hormonal agents, and opioid antagonists are reviewed at a basic science and clinical level. Possible directions for their use in the brain-injured patient are discussed.

KW - Agitation

KW - Brain injury

KW - Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=0342774665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342774665&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 233

EP - 244

JO - NeuroRehabilitation

JF - NeuroRehabilitation

SN - 1053-8135

IS - 3

ER -